gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · AYTUHealthcarePharmaceuticals

AYTU BioPharma, Inc. Common Stock (AYTU)

$1.92−0.52%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$1.93▼ 12.67% in range
Nov 3, 2025Low $1.90 · High $2.90Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

AYTU BioPharma closed at $1.92 on Nov 4, down 0.52%, within 1.1% of its 52-week closing low. Volume of 29.1K shares was 1.32× its 20-day average (above normal).

Split-adjusted performance: -6.3% over one month, -25.0% over six months, -13.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $16.11M, up 6.4% from a year earlier, with a net margin of -0.1%.

Short interest was 328.9K shares at the Oct 15 settlement, down 4.7% from the prior report (3.6% of float, 14.0 days to cover).

Market cap$20.9M10.9M shares
Revenue · quarter$16.1M+6.4% YoY
Diluted EPS$0.00—
P/E · TTM—P/S 0.4×
Net margin-0.1%Gross 64.6%
Dividend yieldNone
52-week range1.90 – 2.90−33.8% from high
Volume29.1K1.32× 20-day avg
Volatility · 60d36.8%Annualised
Short % of float3.6%14.0 days to cover
Net cash$9.3MCash $26.3M
Next earnings—Not scheduled
Split-adjusted performance
1W −2.5%1M −6.3%3M −17.6%6M −25.0%YTD −26.2%1Y −13.1%3Y −28.1%5Y −96.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum50
Revenue growth51
Net margin69
Value (low P/E)—
Size22

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short328.9K−4.7% vs prior
Days to cover14.0Settled Oct 15
% of float3.6%
Short vol. 10d32.0%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
AYTUAYTU BioPharma$1.92−0.52%−25.0%+6.4%−0.1%—$20.9M
EDSAEdesa Biotech$2.17−4.82%−85.5%———$20.9MCompare
MCRBSeres Therapeutics$2.09+6.63%−73.9%—622.4%—$21.0MCompare
TXMDTherapeuticsMD$1.82+2.25%−10.3%−8.7%17.8%—$21.1MCompare
ATOSAtossa Therapeutics$2.12−9.01%−63.4%———$21.2MCompare
IGCIGC Pharma$0.1950+4.84%−38.7%−19.2%−1107.9%—$20.2MCompare
COCPCocrystal Pharma$1.01−5.61%−28.4%—−3013.3%—$19.5MCompare
CNTXContext Therapeutics$0.2035+4.90%−91.6%———$18.7MCompare
MIRAMIRA Pharmaceuticals$0.5610+8.34%−43.9%———$23.6MCompare

News about AYTU BioPharma

All news →
Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?Zacks Investment Research · Oct 7, 2026NeutralAytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue EstimatesZacks Investment Research · Sep 22, 2026Neutral

Quick answers

What does AYTU BioPharma do?
Aytu BioPharma Inc is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. It has single operating segment.
What is AYTU's market cap?
$20.86M, based on the Nov 4 close of $1.92.
Does AYTU BioPharma pay a dividend?
No regular cash dividend has been paid in the last year.
How much of AYTU is sold short?
328.9K shares, 3.6% of float, as of Oct 15, 2026.
What sector is AYTU in?
Healthcare, in the Pharmaceuticals industry.

About AYTU BioPharma

Aytu BioPharma Inc is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. It has single operating segment. Its product portfolio includes EXXUA, ADHD Portfolio, Pediatric Portfolio, and Other. Majority of revenue comes from ADHD Portfolio. It has presence in United States.

HQ: Denver, CO76 employeesListed Feb 15, 2008aytubio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology